New hope for advanced gynecologic cancers: testing a Triple-Threat drug combo
NCT ID NCT07054567
Summary
This study is testing a new combination of drugs (BL-B01D1, pembrolizumab, and sometimes bevacizumab) for women with advanced cervical or endometrial cancer that has returned or spread. The goal is to see if this combination can shrink tumors and control the disease better than current options, while monitoring side effects. It will include about 96 participants to find the most effective and safe dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.